Health
Russia’s COVID-19 vaccine shows over 91% efficacy in phase 3 trial: Lancet study – The Tribune India
Findings based on analysis of data from nearly 20,000 participants; Sputnik V is a two-part vaccine that includes two adenovirus vectors
Moscow, February 2
Russia’s Sputnik V vaccine against COVID-19 has shown 91.6 per cent efficacy in the phase 3 trial without any serious side effects, according to an interim analysis of data published in The Lancet journal on Tuesday.
The findings are based on analysis of data from nearly 20,000 participants – three-quarters of whom received the two-dose regimen of the adenovirus-based vaccine, Gam-COVID-Vac, and one quarter received a placebo.
Serious adverse events or those requiring hospital…
-
General11 hours agoRSL NSW president Mick Bainbridge and three board members resign in wake of 7.30 investigation into conflicts of interest
-
General14 hours agoSelf-taught child drummer makes rock band debut with The Living End
-
Noosa News18 hours agoWave of cruises headed for Sunshine Coast this summer
-
General22 hours agoNewsCorp executive warns AI firms are asking Australia to ‘surrender our stories’